Querying Automated Antibiotic Susceptibility Testing Instruments: A Novel Population-Based Active Surveillance Method for Multidrug-Resistant Gram-Negative Bacilli

Objective. To describe the implementation of a population-based surveillance system for multidrug-resistant gram-negative bacilli (MDR-GNB). Design. Population-based active surveillance by the Georgia Emerging Infections Program. Setting. Metropolitan Atlanta, starting November 2010. Patients. Residents with MDR-GNB isolated from urine or a normally sterile site culture. Methods. Surveillance was implemented in 3 phases: (1) surveying laboratory antibiotic susceptibility testing practices, (2) piloting surveillance to estimate the proportion of GNB that were MDR, and (3) maintaining ongoing active surveillance for carbapenem-nonsusceptible Enterobacteriaceae and Acinetobacter baumannii using the 2010 Clinical and Laboratory Standards Institute (CLSI) breakpoints. Pilot surveillance required developing and installing queries for GNB on the 3 types of automated testing instruments (ATIs), such as MicroScan, in Atlanta's clinical laboratories. Ongoing surveillance included establishing a process to extract data from ATIs consistently, review charts, manage data, and provide feedback to laboratories. Results. Output from laboratory information systems typically used for surveillance would not reliably capture the CLSI breakpoints, but queries developed for the 3 ATIs did. In November 2010, 0.9% of Enterobacteriaceae isolates and 35.7% of A. baumannii isolates from 21 laboratories were carbapenem nonsusceptible. Over a 5-month period, 82 Enterobacteriaceae and 59 A. baumannii were identified as carbapenem nonsusceptible. Conclusions. Directly querying ATIs, a novel method of active surveillance for MDR-GNB, proved to be a reliable, sustainable, and accurate method that required moderate initial investment and modest maintenance. Ongoing surveillance is critical to assess the burden of and changes in MDR-GNB to inform prevention efforts.

[1]  S. Cosgrove,et al.  Outcomes of Children With Enterobacteriaceae Bacteremia With Reduced Susceptibility to Ceftriaxone: Do the Revised Breakpoints Translate to Improved Patient Outcomes? , 2013, The Pediatric infectious disease journal.

[2]  E. Böttger,et al.  Influence of Clinical Breakpoint Changes from CLSI 2009 to EUCAST 2011 Antimicrobial Susceptibility Testing Guidelines on Multidrug Resistance Rates of Gram-Negative Rods , 2013, Journal of Clinical Microbiology.

[3]  Ronald N. Jones,et al.  Prevalence of β-Lactamase-Encoding Genes among Enterobacteriaceae Bacteremia Isolates Collected in 26 U.S. Hospitals: Report from the SENTRY Antimicrobial Surveillance Program (2010) , 2013, Antimicrobial Agents and Chemotherapy.

[4]  Michael Bell,et al.  Vital Signs: Carbapenem-Resistant Enterobacteriaceae , 2013, MMWR. Morbidity and mortality weekly report.

[5]  H. Humphreys,et al.  Priorities in the prevention and control of multidrug-resistant Enterobacteriaceae in hospitals. , 2012, The Journal of hospital infection.

[6]  G. Bloemberg,et al.  Effects of clinical breakpoint changes in CLSI guidelines 2010/2011 and EUCAST guidelines 2011 on antibiotic susceptibility test reporting of Gram-negative bacilli. , 2012, The Journal of antimicrobial chemotherapy.

[7]  Thierry Naas,et al.  Global Spread of Carbapenemase-producing Enterobacteriaceae , 2011, Emerging infectious diseases.

[8]  G. B. Orsi,et al.  Surveillance and management of multidrug-resistant microorganisms , 2011, Expert review of anti-infective therapy.

[9]  P. Della‐Latta,et al.  Carbapenem-resistant Klebsiella pneumoniae bacteremia: factors correlated with clinical and microbiologic outcomes. , 2010, Diagnostic microbiology and infectious disease.

[10]  P. Higgins,et al.  Global spread of carbapenem-resistant Acinetobacter baumannii. , 2010, The Journal of antimicrobial chemotherapy.

[11]  M. Synnestvedt,et al.  Risk Factors and Clinical Impact of Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae , 2009, Infection Control & Hospital Epidemiology.

[12]  K. Riesenberg,et al.  Attributable Mortality Rate for Carbapenem-Resistant Klebsiella pneumoniae Bacteremia , 2009, Infection Control & Hospital Epidemiology.

[13]  M. Falagas,et al.  Current control and treatment of multidrug-resistant Acinetobacter baumannii infections. , 2008, The Lancet. Infectious diseases.

[14]  Gopi Patel,et al.  Outcomes of Carbapenem-Resistant Klebsiella pneumoniae Infection and the Impact of Antimicrobial and Adjunctive Therapies , 2008, Infection Control & Hospital Epidemiology.

[15]  Yehuda Carmeli,et al.  Predictors of Carbapenem-Resistant Klebsiella pneumoniae Acquisition among Hospitalized Adults and Effect of Acquisition on Mortality , 2007, Antimicrobial Agents and Chemotherapy.

[16]  Yehuda Carmeli,et al.  Clinical and Economic Impact of Common Multidrug-Resistant Gram-Negative Bacilli , 2007, Antimicrobial Agents and Chemotherapy.

[17]  S. Cosgrove,et al.  Multidrug-resistant Acinetobacter Infection Mortality Rate and Length of Hospitalization , 2007, Emerging infectious diseases.

[18]  Ronald N. Jones,et al.  Emergence of serine carbapenemases (KPC and SME) among clinical strains of Enterobacteriaceae isolated in the United States Medical Centers: report from the MYSTIC Program (1999-2005). , 2006, Diagnostic microbiology and infectious disease.

[19]  S. Cosgrove The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  John Quale,et al.  Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium. , 2005, Archives of internal medicine.

[21]  G. Rahav,et al.  Outcome of carbapenem resistant Klebsiella pneumoniae bloodstream infections. , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[22]  Mary Jane Ferraro,et al.  Performance standards for antimicrobial susceptibility testing : twelfth informational supplement , 2002 .